Graceptor is a once-daily modified release formulation of Astellas’s Prograf (tacrolimus, twice-daily formulation). Tacrolimus works as an immunosuppressant by inhibiting activation of T-cell. Graceptor maintains its efficacy and
HealthMedia’s suite of interventions reportedly provides automated web-based coaching for wellness, disease management, behavioral health and medication adherence with proven outcomes, increased compliance, reduced medical utilization, and increased
AVE1642 was developed by ImmunoGen using the company’s expertise in monoclonal antibodies and cancer biology, and was humanized using ImmunoGen’s proprietary resurfacing technology. The compound was licensed to
Preliminary data from a Phase I single ascending dose study of RDEA594 in healthy volunteers showed that oral administration of 100mg of RDEA594 demonstrated a favorable pharmacokinetic profile
According to the company, AP24534 demonstrated potent inhibition of selected kinase targets that control tumor growth and angiogenesis, notably all four receptors for fibroblast growth factors (FGFRs). The
In connection with the transaction, Pacgen would acquire all of the issued and outstanding shares of Medigen by way of share purchase or through such other transaction structure
Results of the Radiate study, which evaluated difficult-to-treat patients who failed to respond to prior anti-tumor necrosis factor (TNF)-alpha therapies, demonstrated that half of the patients treated with
Data presented demonstrate that a single administration of IPI-926 in a preclinical model of human pancreatic cancer results in rapid and sustained Hedgehog pathway inhibition in the stromal
The EU labeling provides for patients who require longer-term therapy to be treated for up to six months, with the usual course of therapy for typical patients being
The data presented are from studies measuring the effectiveness of an orally administered avian flu vaccine designed by Vaxart scientists using the company’s proprietary modular platform. The Vaxart
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.